What question did this study set out to answer?

This review examines venetoclax-based therapies for chronic lymphocytic leukemia (CLL).

Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia

View Full Paper

Ask AI

Bookmark

This review examines venetoclax-based therapies for chronic lymphocytic leukemia (CLL).
Reviewed clinical trials of venetoclax combinations with anti-CD20 antibodies, BTKi, and CAR T-cells.
Analyzed outcomes such as overall response rates and progression-free survival.
VEN-based regimens achieved high overall response rates and durable progression-free survival.
Combination treatments demonstrated substantial rates of undetectable minimal residual disease.
Regimens showed superiority over traditional chemoimmunotherapy, offering prolonged treatment-free intervals.

No takes yet. Share an insight, caveat, or question.

Narrative review shows venetoclax combinations improve overall response rates in CLL, suggesting benefits in treatment-free intervals.

Kegyes et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark